39results about How to "Reduce ability" patented technology

A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.

A device and method for treating bodily conduits involves the application of energy to the smooth muscle tissue of the conduit walls to reduce the bulk of smooth muscle tissue and mucus glands. The irradiation treatment of the smooth muscle tissue causes a reduction in the amount of smooth muscle tissue over time which increases the inner diameter of the body conduit for improved fluid flow and prevents smooth muscle spasms. The treatment is particularly useful in the lungs for treatment of asthma to prevent bronchospasms, increase the airway diameter for improved air exchange, and reduce mucus secretions in the lungs.

There is provided a neural network system for detection of domain generation algorithm generated domain names, the neural network system comprising: an input receiver configured for receiving domain names from one or more input sources; a convolutional neural network unit including one or more convolutional layers, the convolutional unit configured for receiving the input text and processing the input text through the one or more convolutional layers; a recurrent neural network unit including one or more long short term memory layers, the recurrent neural network unit configured to process the output from the convolutional neural network unit to perform pattern recognition; and a classification unit including one or more classification layers, the classification unit configured to receive output data from the recurrent neural network unit to perform a determination of whether the input text or portions of the input text are DGA-generated or benign domain names.

Devices and methods for thermally-mediated treatment of blood vessels to elicit an immune response to cause rapid endothelial growth over at least portions of an implant or stent to prevent adverse events such as restenosis. Devices and methods for thermally-mediated treatment to inhibit contraction of vessels to

The device is a thin, self-adhesive non-stretch splint, having the capability to flex. This device is intended for the treatment of repetitive stress injuries such as Carpal Tunnel Syndrome with elements that provide user adjustable limitation of movement within acceptable medical parameters. Carpal Tunnel Syndrome symptoms include pain and numbness in the thumb, index, and middle fingers, that are aggravated by compression of the median nerve. This device limits flexion, extension, ulnar and radial deviation movements of the wrist without compressing the median nerve The device limits movement by reducing skin elasticity on the surface skin above or below the wrist and up the forearm. The application provides biomechanical feedback to the wearer in the form of the tugging sensation on the skin around the perimeter of the device assisting the user in maintaining a more neutral wrist position without imposing wrist immobilization. The design elements allow the use of the device in such a manner that produces no additional pressure to the median nerve while in use. Furthermore the method of application provides a means for the user to regulate the amount of wrist movement to provide a greater comfort level while still limiting movement within medically proven parameters. The adhesive nature of the device eliminates the need for external straps that normally wrap completely around the forearm and hand to hold a splint in place. The application of the device limits movement by greatly reducing the ability of the skin to stretch by placing a self-adhesive non-stretch splint directly on the skin. The device, and how it is placed utilizes the wearers skin elasticity to provide biomechanical feedback to the user to promote better wrist posture.

Catalysts of the present invention are not corroded in acidic electrolytes or at high potential and have excellent durability and high oxygen reducing ability.The catalyst includes a metal oxycarbonitride containing two metals M selected from the group consisting of tin, indium, platinum, tantalum, zirconium, titanium, copper, iron, tungsten, chromium, molybdenum, hafnium, vanadium, cobalt, cerium, aluminum and nickel, and containing zirconium and / or titanium.

The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

A muzzle brake assembly for a firearm provides several benefits including an ability to reduce firearm recoil by redirecting the propellant gases and reshaping the pressure wave in a new manner, reduction or substantial elimination of muzzle movement upon discharge, lessening the acoustic signature of the firearm closer to non-braked levels and relatively easy and low cost to manufacture by current machining practices thereby minimizing cost of manufacturing. Ports in the muzzle brake assembly are arranged opposing one another about a circumference of the muzzle brake assembly.

In one embodiment, a safety trailer has semi-tractor hitches at both ends and a safety wall that is fixed to one side of the trailer. That side, however, can be changed to the right or left side of the road, depending on the end to which the truck attaches. A caboose can be attached at the end of the trailer opposite the tractor to provide additional lighting and impact protection. Optionally, the trailer can be equipped with overhead protection, lighting, ventilation, onboard hydraulics, compressors, generators and other equipment, as well as related fuel, water, storage and restroom facilities and other amenities.

A support device (1) for supporting a length of material (8) wherein the support device includes: at least one support finger (4,5) for supporting the length of material (8) which applies an initial load to the support finger (5); the support device characterised in that the support finger (5) no longer supports the length of material (8) when the support finger is placed directly or indirectly under a load substantially greater than the initial load.

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

A process for producing metallic fine particles is provided by, the reduction of the metallic ions performed in two steps using two types of reducing agents which significantly differ in reducing ability thereof, in which a reducing agent in which the reduction ability is strong is used in the first reduction step, and a reducing agent in which the reduction ability is weak is used in the second reduction step, and the nano-sized metallic fine particles are produced. An aqueous metallic salt solution containing a surfactant is used and a two-step reduction is performed in the same vessel, in which as the reducing agent of the first reduction process, at least one selected from the group consisting of boron hydride, dimethylamine borane, hydrazine, and ascorbic acid is used, and as the reducing agent of the second reduction process, specific alkylamine or alkanolamine is used.

This invention provides methods of improving myocardial function in a subject after ischemic injury comprising administering G-CSF or SDF-1 to the subject.

A method of producing a carpet or rug pursuant to a tufting process, including tufting pile threads into a tuft substrate, and guiding the back side of the tuft substrate along while pressing the back side, together with the loops of the pile threads pierced through the tuft substrate, against a heated drum. At a predetermined temperature, the loops of the pierced-through pile threads begin to melt, and at a predetermined pressure are pressed flat against the tuft substrate.

A solid rocket motor comprises a pressure vessel, a solid propellant structure within the pressure vessel, and a flight termination system overlying the pressure vessel. The flight termination system comprises a shaped charge configured and positioned to effectuate ignition of an inner portion of the solid propellant structure and a reduction in an ability of the pressure vessel to withstand a change in internal pressure. Another solid rocket motor, a multi-stage rocket motor assembly, and a method of destroying a launch vehicle in flight are also described.

It is an object of the present invention to provide a method for producing a cell medicine that is effective for diseases while causing a low risk to these diseases. The present invention provides a method for producing a phagocyte that expresses a foreign protein, which comprises: a step of introducing a protein expression vector into an induced pluripotent stem cell; and a step of inducing the induced pluripotent stem cell, into which the protein expression vector has been introduced, to differentiate into a phagocyte.

This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the tm-PTPε gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the tm-PTPε gene.

The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilisation or rupture of the bacterial cell wall.The invention further relates to a pharmaceutical composition for treatment of extracellular and / or intracellular microbial infected cells and / or for the prevention of microbial cell infections comprising at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and / or at least one antibiotic affecting the bacterial cell wall or its synthesis, and a substrate carrying a pharmaceutical composition.The invention also relates to the use of a combination of at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and at least one antibiotic affecting the bacterial cell wall or its synthesis as anti-adhesive against microorganisms on surfaces.

A weed deflector for a water intake formed in the lower unit of an outboard motor or stern drive of an inboard outboard engine. The weed deflector includes a fin with a leading edge disposed between a fin base and a tip. A mounting plate fixes the fin base to the lower unit (or stern drive) up flow of the water intake in either a horizontal or vertical orientation. The cross sectional form of the fin induces turbulence in the water flow adjacent to the water intake thereby reducing the ability of debris from obstructing the water intake.

The method and system of the invention is directed to a process for the optional acquisition of receivables. The method of the invention, which may be characterized as an Optional Purchase Commitment (“OPC”) is a process by which a potential grantee, for example a buyer, may pay for the right, but not the obligation, to acquire receivables from a grantor, for example a seller. The OPC process of the invention enables a grantor of such receivables, typically a credit grantor, to estimate the amount of its future receivables and enter into OPC agreements to convey those expected receivables under a fixed arrangement at a specific time in the future to a grantee, for example a buyer. A grantor, a grantee, or a third party acting on behalf of either a grantor or a grantee, or independently, may initiate the OPC process of the invention. The OPC process may be utilized in conjunction with existing marketing processes. The OPC process of the invention provides a time horizon or option period. This time horizon or option period is advantageous for both grantor and grantee. Further, the process of the invention may be used in a third party exchange or clearinghouse, which may be implemented utilizing a computer arrangement.

An organic electroluminescence device comprises a cathode, an anode and a layer of an organic thin film comprising one or a plurality of layers and disposed between the cathode and the anode, wherein at least one of the layers in the layer of an organic thin film comprises a laminate of a layer comprising a metal complex having an energy gap of 2.8 eV or greater and a layer of a host material. The organic electroluminescence device exhibits a higher efficiency of light emission and has a longer life than conventional devices while the emitted light has a high luminance.

The present specification discloses natural repellent compounds, and isomeric forms, structural analogues and derivatives of the said compounds, having repellent activity against mosquitoes and other blood-sucking arthropods, compositions comprising such repellent compounds, methods of screening for such repellent compounds, methods of reducing mosquito bites on an individual and methods of reducing mosquito infestation to a location.

Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1- and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis.

The method and system of the invention is directed to a process for the optional acquisition of receivables. The method of the invention, which may be characterized as an Optional Purchase Commitment (“OPC”) is a process by which a potential grantee, for example a buyer, may pay for the right, but not the obligation, to acquire receivables from a grantor, for example a seller. The OPC process of the invention enables a grantor of such receivables, typically a credit grantor, to estimate the amount of its future receivables and enter into OPC agreements to convey those expected receivables under a fixed arrangement at a specific time in the future to a grantee, for example a buyer. A grantor, a grantee, or a third party acting on behalf of either a grantor or a grantee, or independently, may initiate the OPC process of the invention. The OPC process may be utilized in conjunction with existing marketing processes. The OPC process of the invention provides a time horizon or option period. This time horizon or option period is advantageous for both grantor and grantee. Further, the process of the invention may be used in a third party exchange or clearinghouse, which may be implemented utilizing a computer arrangement.

A surface of a marine object is treated with an antifouling paint. The antifouling paint comprises a porous silicate and a wax. The porous silicate has a particle size of between 1 and 100 μm and is in a concentration of between 18 and 60 weight percent. The antifouling paint is applied to the surface. The wax is used to encapsulate the porous silicate and to prevent an immediate release of ions from the porous silicate.

A folder superstructure includes a former, a first top of former roll located upstream of the former and having a compressible outer layer and a second top of former roll forming a nip with the first top of former roll. A method for operating a printing press is also provided.

A liquid antimicrobial composition is provided for use in the disinfection of the skin of a human or an animal, in particular where disinfection of a drug resistant organism is required. The composition comprises a cationic, cell membrane-disrupting biocide and a cationic dendrimer capable of inhibiting an efflux pump mechanism of said cell membrane. The cationic, cell membrane-disrupting biocide is preferably any or a combination of chlorhexidine, a polymeric biguanide, octenidine dihydrochloride and a quaternary ammonium compound. The dendrimer is provided to bind and disrupt the cell membranes of microorganisms in order to inhibit or destroy the cell's efflux pump mechanism thereby preventing microorganism strains resistant to the cationic membrane-disrupting biocide from becoming prevalent, particularly if the biocide comprises chlorhexidine. The dendrimer is preferably a G-0 to G-3 dendrimer comprising any or a combination of quaternary ammonium functionalised poly(propylene imine), polylysine, dendrimers with surface groups based on a sugar and polyamide amine (PAMAM) dendrimers. The composition is preferably in the form of an aqueous or aqueous alcohol solution, dispersion or emulsion that may have been adsorbed by a wipe.